247-22 | Randomized Study to Demonstrate the Efficacy and Safety of an Oral Factor Xia Inhibitor, after an Ischemic Stroke or High Risk Transient Ischemic Attack

Overview

“A Phase 3, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of an Oral Factor Xia Inhibitor, after an Ischemic Stroke or High Risk Transient Ischemic Attack”

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.